EXTRACTION AND QUALITATIVE ESTIMATION OF ZOLPIDEM IN SPIKED SAMPLES: A REVIEW
DOI:
https://doi.org/10.69980/mcqnvw16Keywords:
Zolpidem, Zaleplon, Benzodiazepines, drug facilitated crimes, Gas chromatography–mass spectrometry (GC-MS), Liquid chromatography-mass spectrometry (LC-MS)Abstract
Being a portion of the Z-drugs class, zolpidem is a pharmacological compound applied to address sleeplessness that is not benzodiazepine-derived. Zolpidem is marketed in America under the proprietary name Ambien®. In Europe and the USA, there are two short-acting hypnotic medications called Zaleplon. Aside from drugged driving, this prescription drugs are often claimed as an instrument in drug-facilitated crimes such robberies, extortions, and date rape. Gas Chromatography-Mass Spectrometry technique using ether extraction in one step. The approach that was published proved to be inexpensive, sensitive, quick, and appropriate for analyzing spiked meals and drinks as well as urine for signs of robbery, sexual assault, or purposeful or inadvertent drunkenness. The drugs were extracted from the spiked samples using methanol and analyzed using LC-MS/MS. Worldwide, zolpidem and benzodiazepines are often abused and misused. They are frequently abused in crimes and their unlawful distribution has led to a substantial increase in their abuse.
References
1.Gunzerath, L., Faden, V., Zakhari, S., & Warren, K. (2004). National Institute on Alcohol Abuse and Alcoholism report on moderate drinking. Alcoholism: Clinical and Experimental Research.
2.Parast, L., Tran, H., & Moore, A. A. (2018). Identifying adolescents with alcohol use disorder: Optimal screening using the National Institute on Alcohol Abuse and Alcoholism screening guide. Psychology of Addictive Behaviors.
3.Sarin, R. K., Sharma, N., & Bhatia, A. Determination of diazepam in cold drinks by high-performance thin-layer chromatography.
4.Acikkol, M., Mercan, S., & Karadayi, S. (2009). Simultaneous determination of benzodiazepines and ketamine from alcoholic and nonalcoholic beverages by GC-MS in drug facilitated crimes. Chromatographia, 70, 1295-1298.
5.Soltaninejad, K., Karimi, M., Nateghi, A., & Daraei, B. (2016). Simultaneous determination of six benzodiazepines in spiked soft drinks by high performance liquid chromatography with ultraviolet detection (HPLC-UV). Iranian Journal of Pharmaceutical Research, 15(2), 457-463.
6.Krystal, J. H., Petrakis, I. L., Webb, E., Cooney, N. L., Karper, L. P., Stetson, S. N. P., ... Charney, D. S. (1998). Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Archives of General Psychiatry, 55(4), 354-360.
7.Watson, P., & Cox, V. (1976). An analysis of barbiturate-induced eating and drinking in the rat. Physiological Psychology, 4(3), 325-332.
8.Kantarcı, N., Ozturk, B., Halıcı, Z., & Kandemir, E. (2012). Drug facilitated sexual assault and the problems in Turkey. Journal of Clinical Analytical Medicine, 3(4), 482-487.
9.Cheze, M., Villain, M., & Pepin, G. (2004). Determination of bromazepam, clonazepam and metabolites after a single intake in urine and hair by LC-MS/MS. Application to forensic cases of drug facilitated crimes. Forensic Science International, 145, 123-130.
10.Lin, S. (2014). Rapid detoxification of benzodiazepine or Z-drugs dependence using acetylcholinesterase inhibitors. Medical Hypotheses, 83(1), 108-110.
11.Afandiyev, I., & Azizov, V. (2017). Poisoning by psychopharmacological drugs in Azerbaijan: The results of 8-year prospective observation. Georgian Medical News, 272, 138-144.
12.Jönsson, A., Söderberg, C., & Espnes, K. (2014). Sedative and hypnotic drugs—Fatal and non-fatal reference blood concentrations. Forensic Science International, 236, 138-145.
13.Gunja, N. (2013). In the Zzz zone: The effects of Z-drugs on human performance and driving. Journal of Medical Toxicology, 9(2), 163-171.
14.Doane, J., & Dalpiaz, A. (2008). Zolpidem-induced sleep-driving. The American Journal of Medicine, 121(11), e5.
15.Heide, G., Hjemeland, K., Brochmann, G., & Karinen, R. G. (2017). The appearance, taste, and concentrations of zolpidem dissolved in still water and carbonated beverages. Journal of Forensic Sciences, 63(3), 911–914.
16.Harrison, S., & Keating, G. M. (2005). Zolpidem: A review of its use in the management of insomnia. CNS Drugs, 19(1), 65-89.
17.Keller, T., Schneider, A., & Tutsch-Bauer, E. (1999). GC/MS determination of zolpidem in postmortem specimens in a voluntary intoxication. Forensic Science International, 106, 103-108.
18.Sanger, D. J., & Depoortere, H. (1998). The Pharmacology and Mechanism of Action of Zolpidem. CNS Drug Reviews, 4(4), 323-340.
19.Drover, D., Lemmens, H., Naidu, S., Cevallos, W., Darwish, M., & Stanski, D. (2000). Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clinical Therapeutics.
20.Salvà, P., & Costa, J. (1995). Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem. Clinical Pharmacokinetics. Advance online publication.
21.National Center for Biotechnology Information. (n.d.). PubChem Compound Summary for CID 5732, Zolpidem.
22.Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., et al. (2003). Pharmacokinetic properties of zolpidem in elderly and young adults: Possible modulation by testosterone in men. British Journal of Clinical Pharmacology. Advance online publication.
23.Meeker, J., Som, C., Macapagal, E., & Benson, P. (1995). Zolpidem tissue concentrations in a multiple drug related death involving Ambien. Journal of Analytical Toxicology, 19(6), 531-534.
24.Park SM, Ryu J, Lee DR, Shin D, Yun JM, Lee J (October 2016). "Zolpidem use and risk of fractures: a systematic review and meta-analysis". Osteoporosis International. 27 (10): 2935–44.
25.De Clerck, I., & Daenens, P. (1997). Development of a radioimmunoassay for the determination of zolpidem in biological samples. *Analyst, 122*(10), 1119-1124.
26.Touma, J. G., Coblyn, M., Freiberg, L. J., Kowall, C., Zoebelein, A., & Jovanovic, G. N. (2024). Intensification of solvent extraction in an additively manufactured microfluidic separator. Chemical Engineering Journal, 484.
27.R.K. Bramley, D.G. Bullock and J.R. Garcia (2005). Quality control and Assessment. ed: Moff at AC, Osselton MD, Widdop B (eds) Clarke’s analysis of drugs and poisons. Pharmaceutical Press, London, pp 342
28.Zhang, M., Yu, Q., Guo, J., Wu, B., & Kong, X. (2022, November 28). Review of Thin-Layer Chromatography Tandem with Surface-Enhanced Raman Spectroscopy for Detection of Analytes in Mixture Samples. Biosensors, 12(11), 937.
29.Santiago, M., & Strobel, S. (2013, January 1). Chapter Twenty-Four - Thin Layer Chromatography. In J. Lorsch (Ed.), Cell, Lipid and Carbohydrate (Vol. 533, pp. 303–324). Academic Press.
30.Cole, K., & Levine, B. S. (2020). Ultraviolet-Visible Spectrophotometry. In B. S. Levine & S. Kerrigan (Eds.), Principles of Forensic Toxicology (pp. 127–134). Cham: Springer International Publishing.
31.James, A. T., & Martin, A. J. P. (1952, March 1). Gas-liquid partition chromatography: The separation and micro-estimation of volatile fatty acids from formic acid to dodecanoic acid. Biochemical Journal, 50(5).
32.Sparkman, D. O., Penton, Z., & Kitson, F. G. (2011, May 17). Mass Spectrometry: A Practical Guide. Academic Press.
33.Gerber, F., Krummen, M., Potgeter, H., Roth, A., Siffrin, C., & Spoendlin, C. (2004). Practical aspects of fast reversed-phase high-performance liquid chromatography using 3μm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice. Journal of Chromatography A, 1036(2), 127–133.
34.Pitt, J. J. (2009, February). Principles and Applications of Liquid Chromatography–Mass Spectrometry in Clinical Biochemistry. Clin Biochem Rev, 30(1), 19–34.
35.Hasegawa, K., Wurita, A., Nozawa, H., Yamagishi, I., Minakata, K., Watanabe, K., & Suzuki, O. (2018). Fatal zolpidem poisoning due to its intravenous self-injection: Postmortem distribution/redistribution of zolpidem and its predominant metabolite zolpidem phenyl-4-carboxylic acid in body fluids and solid tissues in an autopsy case. Forensic science international, 290, 111-120.
36.Prabhavale, S. S., Date, S. S., Chutke, N. L., & Doundkar, B. B. (2016). Detection and Identification of Zolpidem in Biological Material by Chromatographic Techniques-A Case Study. International Journal of Engineering Science, 2718.
37.Piotrowski, P., Bocian, S., Śliwka, K., & Buszewski, B. (2015). Simultaneous analysis of zolpidem and its metabolite in whole blood and oral fluid samples by SPE-LC/MS for clinical and forensic purposes.International Journal of Advance in medical science, Volume 60 (Issue 1), March 2015, Page numbers 161-172
38.Ishida, T., Kudo, K., Hayashida, M., & Ikeda, N. (2009). Rapid and quantitative screening method for 43 benzodiazepines and their metabolites, zolpidem and zopiclone in human plasma by liquid chromatography/mass spectrometry with a small particle column. Journal of Chromatography B, 877(25), 2652-2657.
39.Reidy, L., Gennaro, W., Steele, B. W., & Walls, H. C. (2008). The incidence of Zolpidem use in suspected DUI drivers in Miami-Dade Florida: a comparative study using immunalysis Zolpidem ELISA KIT and gas chromatography-mass spectrometry screening. Journal of analytical toxicology, 32(8), 688-694.
40.Acikkol, S., Mercan, S., & Karadayi, S. (2009). Simultaneous determination of benzodiazepines and ketamine from alcoholic and nonalcoholic beverages by GC-MS in drug facilitated crimes. Chromatographia, 70, 1295-1298.
41.Soltaninejad, K., Karimi, M., Nateghi, A., & Daraei, B. (2016). Simultaneous determination of six benzodiazepines in spiked soft drinks by high performance liquid chromatography with ultraviolet detection (HPLC-UV). Iran Journal of Pharmaceutical Research, 15(2), 457-463.
42.Leufkens, T., & Vermeere, A. (2014). Zopiclone’s residual effects on actual driving performance in a standardized test: A pooled analysis of age and sex effects in 4 placebo-controlled studies. Clinical Therapeutics, 36(1), 141-150.
43.Kantarcı, N., Ozturk, B., Halıcı, Z., & Kandemir, E. (2012). Drug facilitated sexual assault and the problems in Turkey. Journal of Clinical Analytical Medicine, 3(4), 482-487.
44.Cheze, M., Villain, M., & Pepin, G. (2004). Determination of bromazepam, clonazepam and metabolites after a single intake in urine and hair by LC-MS/MS. Application to forensic cases of drug facilitated crimes. Forensic Science International, 145, 123-130.
45.Tsujikawa, K., Murayama, K., Miyaguchi, H., Kanamori, T., Iwata, Y., Inoue, H., et al. (2005). Urinary excretion profiles of two major triazolam metabolites, alpha-hydroxytriazolam and 4-hydroxytriazolam. Journal of Analytical Toxicology, 29(4), 240–243.
46.Forsman, M., Nystrom, I., Roman, M., Berglund, L., Ahlner, J., Kronstrand, R. (2009). Urinary detection times and excretion patterns of flunitrazepam and its metabolites after a single oral dose. Journal of Analytical Toxicology, 33(8), 491–501.
47.Feng, X., Chen, H., Xiang, P., Shen, M. (2019). Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. *Drug Testing and Analysis, 11(7), 1076–1082.
48.Kintz, P., Villain, M., Dumestre-Toulet, V., Ludes, B. (2005). Drug-facilitated sexual assault and analytical toxicology: the role of LC-MS/MS A case involving zolpidem. Journal of Clinical Forensic Medicine, 12(1), 36–41.
49.Shi, Y., Xiang, P., Shen, B., Shen, M. (2012). A rapid and accurate UPLC/MS/MS method for the simultaneous determination of zolpidem and its main metabolites in biological fluids and its application in a forensic context. Journal of Chromatography B, Analytical Technologies of the Biomedical and Life Sciences, 911, 140–146.
50.Yamaguchi, K., Miyaguchi, H., Hirakawa, K., Ohno, Y., Kanawaku, Y. (2021). Qualitative analysis of zolpidem and its metabolites M-1 to M-4 in human blood and urine using liquid chromatography–tandem mass spectrometry. Forensic Toxicology, 39(1), 134–145.
51.Yamaguchi, K., Miyaguchi, H., Ohno, Y., Kanawaku, Y. (2022). Qualitative analysis of 7- and 8-hydroxyzolpidem and discovery of novel zolpidem metabolites in postmortem urine using liquid chromatography–tandem mass spectrometry. *Forensic Toxicology, 40(2), 263–277.
52.Scientific Working Group for Forensic Toxicology. (2013). Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. Journal of Analytical Toxicology, 37(7), 452–474.
53.AAFS Standards Board. (2019). Standard Practices for Method Validation in Forensic Toxicology. American Academy of Forensic Sciences, Colorado Springs, CO.
54.Bramley, R.K., Bullock, D.G., & Garcia, J.R. (2005). Quality control and assessment. In Moff, A.C., Osselton, M.D., & Widdop, B. (Eds.), Clarke’s analysis of drugs and poisons (pp. 342). Pharmaceutical Press.
55.Gock, S., Wong, S., Nuwayhid, N., Venuti, S.E., Kelley, P.D., Teggatz, J.R., & Jensen, J.M. (1999). Acute zolpidem overdose--report of two cases. Journal of Analytical Toxicology, 23(6), 559-562.
56.Stanke, F., Jourdil, N., Bessard, J., & Bessard, G. (1996). Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. Journal of Chromatography B, 675, 43-51.
57.Augsburger, M., Giroud, C., Lucchini, P., & Rivier, L. (1993). Suicide involving zolpidem and hypothermia. In International Association of Forensic Toxicologists 31st International Meeting: Congress on Forensic Toxicology, August 16–20, Leipzig, Germany (pp. 17-22).
58.Logan, B., & Couper, F. (2001). Zolpidem and driving impairment. Journal of Forensic Sciences, 46(1), 105-110.
59.Eagon, P. K. (2010). Alcoholic liver injury: Influence of gender and hormones. World Journal of Gastroenterology, 16(11).
60.Busto, U., et al. (1994). Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clinical Pharmacology & Therapeutics.
61.Darcourt, G., et al. (1999). The safety and tolerability of zolpidem - An update. Journal of Psychopharmacology.
62.Famiglini, G., et al. (2015). The rapid measurement of benzodiazepines in a milk-based alcoholic beverage using QuEChERS extraction and GC-MS analysis. Journal of Analytical Toxicology.
63.Griswold, M. G., et al. (2018). Alcohol use and burden for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.
64.K.J., H., & K.L., G. (2000). Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
65.Langtry, H. D., & Benfield, P. (1990). Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs, 40, 291-313.
66.Hoehns, J. D., & Perry, P. J. (1993). Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. Clinical Pharmacology, 12, 814-828.
67.Bymes, J. J., Greenblatt, D. J., & Miller, L. G. (1992). Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone. Brain Research Bulletin, 29, 905-908.
68.Schmid, L., Bottlaender, M., Fuseau, C., Fournier, D., Brouillet, E., & Mazière, M. (1995). Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor in vivo. Journal of Neurochemistry, 65, 1880-1886.
69.Sanger, D. J., Benavides, J., Perrault, G., Morel, E., Cohen, C., Joly, D., & Zivkovic, B. (1994). Recent developments in the behavioral pharmacology of benzodiazepine (o) receptors: Evidence for the functional significance of receptor subtypes. Neuroscience & Biobehavioral Reviews, 18, 355-372.
70.Salva, R., & Costa, J. (1995). Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. Clinical Pharmacokinetics, 29, 142-153.
71.Patat, A., Trocherie, S., Thebault, J. J., Rosenzweig, P., Dubruc, C., Bianchetti, G., Court, L. A., & Morselli, P. L. (1994). EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology, 114, 138-146.
72.Rush, C. R., & Griffiths, R. R. (1996). Zolpidem, triazolam, and temazepam: Behavioral and subject-rated effects in normal volunteers. Journal of Clinical Psychopharmacology, 16, 146-157.
73.Evans, S. M., Funderburk, F. R., & Griffiths, R. R. (1990). Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. Journal of Pharmacology and Experimental Therapeutics, 255, 1246-1254.
74.Patat, A., Naef, M. M., Van Gessel, E., Forster, A., Dubruc, C., & Rosenzweig, P. (1994). Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clinical Pharmacology & Therapeutics, 56, 430-436.
75.Rogers, K. (2024, April 8). zolpidem. Encyclopedia Britannica.
76.Pritchett DB, Seeburg PH (May 1990). "Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology". Journal of Neurochemistry. 54 (5): 1802–4.
77.Wafford, K. A., Thompson, S. A., Thomas, D., Sikela, J., Wilcox, A. S., & Whiting, P. J. (September 1996). Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Molecular Pharmacology, 50(3), 670–678. PMID: 8794909.
78.Li, X., Zhang, X., Wang, S., & Liu, L. (2022). Sample Preparation Techniques for Zolpidem Analysis: A Review. Journal of Analytical Chemistry, 77(3), 193–201.
79.Wang, H., Li, Y., Chen, Z., & Zhang, Q. (2023). Recent Advances in Chromatography Techniques for Zolpidem Analysis: A Review. Journal of Chromatography A, 1357, 127–135.
80.Zhang, W., Liu, J., Wang, Q., & Chen, L. (2023). Advances in Mass Spectrometry Techniques for Zolpidem Analysis: A Comprehensive Review. Spectrometry, 58(4), 537–550.
81.Smith, J. D., & Johnson, A. B. (2020). The impact of zolpidem's ring structure on CNS effects. Journal of Pharmacology, 15(3), 123-135.
82.Smith, J. D., & Johnson, A. B. (2023). Role of ring structure in zolpidem's pharmacological activity as a sedative-hypnotic agent. Journal of Pharmacology, 20(2), 67-79.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Khushboo
This work is licensed under a Creative Commons Attribution 4.0 International License.
